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1. Introduction
Squamous cell carcinoma (SCC) is one of the most encountered types of cancers 
worldwide. It is an aggressive disease that affects the majority of the human body 
organs including the lungs, head and neck, esophagus, skin, genitourinary tract, 
thyroid, and other parts. SCC is a highly metastasizing disease with a relatively low 
overall survival rate. In addition to the traditional chemotherapy and radiotherapy, 
a combination of treatment modalities endeavors to ameliorate the survival rate of 
its various subtypes [1, 2]. Immunotherapy also tries to take part in SCC therapy by 
demonstrating durable improvements by hindering the immune system inhibitory 
interaction between the programmed cell death protein 1 (PD-1) and its ligand 
PD-L1 in the cells [3]. Moreover, the targeted inhibition of the cell signaling path-
ways as the PI3K and the MAPK has proven a novel promising therapeutic domain 
[4, 5]. Cyclin-dependent kinase (CDK) 4/6 inhibitors are another new group of 
small molecules targeting the cyclin D1-CDK4/6-Rb pathway involved in the cell 
cycle control [6, 7].
Oral squamous cell carcinoma is considered among the six most common 
cancers in the world. It is a subgroup of the upper aerodigestive tract and mostly 
affects the anterior tongue with the cheek, the floor of the mouth, the retromolar 
space, the gingiva, or any other part of the oral cavity [8]. The etiology and patho-
genesis of all head and neck squamous cell carcinomas are majorly influenced by 
environmental and lifestyle risk factors, including tobacco use, excessive alcohol 
consumption, papilloma virus infection (predominantly HPV 16), and exposure 
to toxic substances, in addition to other dietary factors as salt-preserved food [9]. 
The esophageal squamous cell carcinoma is similarly affected by environmental and 
lifestyle-related factors such as tobacco use; alcohol overconsumption; salt-pickled 
or salt-cured and moldy foods; carcinogens as nitrosamines, polycyclic aromatic 
hydrocarbons, aromatic amines, various aldehydes, and phenols; vitamin (A, C, E, B) 
and mineral (zinc, selenium) deficiencies; extremely hot beverages; and fungal 
and HPV (16, 18) infections [10]. Human papilloma virus infection has also been 
implicated in the etiology of anal squamous cell carcinoma and especially in HIV-
infected individuals, smokers, sexually perverted intercourses, and multi-sexual 
partners [11]. HPV infection is not known to be associated with the development of 
cutaneous squamous cell carcinoma; some sporadic cases, however, have suggested 
that cutaneous infection with HPV in immunocompetent hosts is prevalent in 
SCC development [12]. Other known risk factors implicated in SCC manifestation 
are exposure to solar ultraviolet radiation (UVR) and tanning bed usage, especially 
in the fair skin population [12–14]. Older age, male gender, cigarette smoking, 
chronic skin ulcers, and burn scars are also documented risk factors [12, 15]. 
Immunocompromised patients with organ transplantations are also at high risk of 
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developing SCC [12, 13]. Moreover, some genetic disorders as the recessive dystro-
phic epidermolysis bullosa, which is caused by loss-of-function mutations in the 
collagen type VII (C7), can lead to the appearance of aggressive form of cutaneous 
squamous cell carcinoma [16, 17]. Actinic keratoses, a form of premalignant lesions 
directly related to skin photodamage, are highly associated to SCC development as 
well [18].
In the following chapters, deepest information with each of these SCC sub-
groups will be widely discussed in order to decipher the basic data behind their 
mechanism of pathogenesis and possible therapeutic modalities. Nowadays, a 
variety of new therapeutic approaches based on genetic identification has proven 
efficacy in prolonging disease-free survival and was adopted in different scientific 
establishments. Targeted and immunotherapies have succeeded to add a fingerprint 
to the traditional chemo- and radiotherapies in prolonging the overall survival of 
many cancer types, even though a considerable amount of side effects has to be 
taken into consideration. This book, therefore, was designed to cover information 
related to SCC, including types, classifications, diagnostic methods, staging, and 
treatment, and to highlight the newest approved therapeutical methodologies, with 
the ongoing promising clinical trials that may add value to the existing treatments.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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